Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2014; 20(33): 11700-11712
Published online Sep 7, 2014. doi: 10.3748/wjg.v20.i33.11700
Advances in the management of peritoneal mesothelioma
Ali Raza, Wei-Ching Huang, Kazuaki Takabe
Ali Raza, Wei-Ching Huang, Kazuaki Takabe, Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA 23298-0011, United States
Author contributions: All authors generated the ideas and contributed to the writing of this paper.
Supported by United States National Institute of Health, No. R01CA160688; and Susan G Komen Investigator Initiated Research Grant, No. IIR12222224 to Kazuaki Takabe
Correspondence to: Kazuaki Takabe, MD, PhD, FACS, Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and Massey Cancer Center, PO Box 980011, West Hospital 7-402, 1200 East Broad Street, Richmond, VA 23298-0011, United States. ktakabe@vcu.edu
Telephone: +1-804-8289322  Fax: +1-804-8284808
Received: December 21, 2013
Revised: March 21, 2014
Accepted: June 2, 2014
Published online: September 7, 2014
Processing time: 260 Days and 7.6 Hours
Core Tip

Core tip: Peritoneal mesothelioma (PM) historically has been associated with a very poor prognosis. Cytoreduction with hyperthermic intraperitoneal chemotherapy improved survival outcomes but carries significant morbidity. Increasingly, research has focused on identifying molecular targets and only a handful have been described; even fewer directed therapies have been evaluated. We review the role of sphingosine kinase 1 and sphingosine-1-phosphate (S1P) signaling in PM and discuss the possibility of targeting it with FTY720, a functional antagonist of S1P Receptor 1. Further investigation is warranted in this new avenue of interest.